[go: up one dir, main page]

DE60103974D1 - Gyrase-inhibitoren und ihre verwendung - Google Patents

Gyrase-inhibitoren und ihre verwendung

Info

Publication number
DE60103974D1
DE60103974D1 DE60103974T DE60103974T DE60103974D1 DE 60103974 D1 DE60103974 D1 DE 60103974D1 DE 60103974 T DE60103974 T DE 60103974T DE 60103974 T DE60103974 T DE 60103974T DE 60103974 D1 DE60103974 D1 DE 60103974D1
Authority
DE
Germany
Prior art keywords
gyrase inhibitors
gyrase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60103974T
Other languages
English (en)
Other versions
DE60103974T2 (de
Inventor
Paul Charifson
Dean Stamos
Michael Badia
Anne-Laure Grillot
Steven Ronkin
Martin Trudeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of DE60103974D1 publication Critical patent/DE60103974D1/de
Application granted granted Critical
Publication of DE60103974T2 publication Critical patent/DE60103974T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60103974T 2000-01-18 2001-01-16 Gyrase-inhibitoren und ihre verwendung Expired - Lifetime DE60103974T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17667100P 2000-01-18 2000-01-18
US176671P 2000-01-18
US25433100P 2000-12-08 2000-12-08
US254331P 2000-12-08
PCT/US2001/001374 WO2001052845A1 (en) 2000-01-18 2001-01-16 Gyrase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
DE60103974D1 true DE60103974D1 (de) 2004-07-29
DE60103974T2 DE60103974T2 (de) 2005-06-30

Family

ID=26872470

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60103974T Expired - Lifetime DE60103974T2 (de) 2000-01-18 2001-01-16 Gyrase-inhibitoren und ihre verwendung

Country Status (23)

Country Link
US (2) US6608087B1 (de)
EP (1) EP1251848B1 (de)
JP (1) JP2003520233A (de)
CN (1) CN1230166C (de)
AR (1) AR027518A1 (de)
AT (1) ATE269701T1 (de)
AU (1) AU782883B2 (de)
BR (1) BR0107713A (de)
CA (1) CA2397686A1 (de)
CO (1) CO5261612A1 (de)
DE (1) DE60103974T2 (de)
DK (1) DK1251848T3 (de)
EA (1) EA005680B1 (de)
ES (1) ES2222336T3 (de)
HK (1) HK1053984B (de)
MX (1) MXPA02007134A (de)
MY (1) MY133572A (de)
NZ (1) NZ520628A (de)
PT (1) PT1251848E (de)
SI (1) SI1251848T1 (de)
TR (1) TR200401735T4 (de)
TW (1) TWI287449B (de)
WO (1) WO2001052845A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095958A1 (en) * 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
US7138403B2 (en) * 2001-08-13 2006-11-21 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
FR2865733B1 (fr) * 2004-02-04 2007-10-12 Merck Sante Sas Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
CA2587224A1 (en) * 2004-11-19 2006-05-26 Plant Bioscience Limited Microcin b17 analogs and methods for their preparation and use
CA2598423C (en) 2005-02-18 2014-05-27 Astrazeneca Ab Antibacterial piperidine derivatives
WO2007095187A2 (en) * 2006-02-13 2007-08-23 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
EP3025653B1 (de) 2006-06-21 2021-06-16 Cook Biotech Incorporated Pfropfen zur behandlung gastrointestinaler fisteln
WO2008019292A2 (en) * 2006-08-04 2008-02-14 Trustees Of Boston University Compositions and methods for potentiating antibiotic activity
TW200906412A (en) * 2007-06-12 2009-02-16 Astrazeneca Ab Piperidine compounds and uses thereof
JP2011502133A (ja) * 2007-11-02 2011-01-20 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
EP2250160B1 (de) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophen-derivate und ihre verwendung als phosphatidylinositol 3-kinase (pi3k) inhibitoren
US8865732B2 (en) * 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
KR20130040258A (ko) * 2008-03-21 2013-04-23 노파르티스 아게 신규한 헤테로시클릭 화합물 및 그의 용도
CA2728095A1 (en) * 2008-07-17 2010-01-21 Asahi Kasei Pharma Corporation Pyrazole-containing tricyclic compounds as antagonists of an ep1 receptor
PE20110843A1 (es) * 2008-09-22 2011-12-08 Cayman Chem Co Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica
TW201026694A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Compound 468
US8071605B2 (en) 2008-12-12 2011-12-06 Astrazeneca Ab Piperidine compounds for use in the treatment of bacterial infections
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) * 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
TW201102065A (en) 2009-05-29 2011-01-16 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
UY32856A (es) 2009-08-26 2011-03-31 Astrazeneca Ab Derivados heterocíclicos de urea y métodos de uso de los mismos
US8907098B2 (en) * 2009-12-17 2014-12-09 Merck Patent Gmbh Inhibitors of sphingosine kinase
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8796268B2 (en) 2010-08-11 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AU2011316016A1 (en) 2010-10-13 2013-05-30 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102911173A (zh) * 2012-11-08 2013-02-06 苏州施亚生物科技有限公司 5,6,7,8-四氢-2H-吡啶并[4,3-c]哒嗪-3-酮的合成方法
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
KR20160115986A (ko) 2014-02-03 2016-10-06 스페로 자이레이스, 인크 폴리믹신을 포함하는 항균성 조합
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
JP7114575B2 (ja) 2016-09-19 2022-08-08 ノバルティス アーゲー Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ
RU2019133662A (ru) 2017-03-24 2021-04-26 Тайсо Фармасьютикал Ко., Лтд. Производное 2(1h)-хинолинона
IL311471A (en) 2017-05-02 2024-05-01 Novartis Ag Combination therapy
US11666555B2 (en) 2017-05-17 2023-06-06 Drexel University RelA inhibitors for biofilm disruption
WO2020048949A1 (en) 2018-09-03 2020-03-12 Univerza V Ljubljani New class of dna gyrase and/or topoisomerase iv inhibitors with activity against gram-positive and gram-negative bacteria
EP4563150A3 (de) 2019-05-13 2025-07-23 Novartis AG Neue kristalline formen von n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonikotinamid als raf-hemmer zur behandlung von krebs
EP4263503A1 (de) 2020-12-17 2023-10-25 Univerza V Ljubljani Neue n-phenylpyrrolamid-inhibitoren der dna-gyrase und topoisomerase iv mit antibakterieller wirkung
NL2033609B1 (en) * 2022-11-24 2024-05-30 Innes John Centre DNA Gyrase Inhibitors
AU2023418987A1 (en) * 2022-12-30 2025-07-03 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors
EP4663242A1 (de) * 2024-06-11 2025-12-17 Helmholtz-Zentrum für Infektionsforschung GmbH Targeting des energiekopplungsfaktor (ecf)-transporters als neues antimikrobielles target

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925659A (en) * 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
CZ287902B6 (cs) * 1996-05-09 2001-03-14 Sankyo Company Limited Léčivo pro prevenci nebo léčbu infekčních chorob vyvolaných Helicobacter pylori

Also Published As

Publication number Publication date
NZ520628A (en) 2004-05-28
ATE269701T1 (de) 2004-07-15
EP1251848B1 (de) 2004-06-23
HK1053984A1 (en) 2003-11-14
AU3094001A (en) 2001-07-31
TR200401735T4 (tr) 2004-08-23
MXPA02007134A (es) 2003-03-27
TWI287449B (en) 2007-10-01
EP1251848A1 (de) 2002-10-30
ES2222336T3 (es) 2005-02-01
CN1400898A (zh) 2003-03-05
AU782883B2 (en) 2005-09-08
EA200200769A1 (ru) 2002-12-26
HK1053984B (zh) 2006-07-28
BR0107713A (pt) 2002-11-19
DK1251848T3 (da) 2004-10-18
DE60103974T2 (de) 2005-06-30
EA005680B1 (ru) 2005-04-28
CO5261612A1 (es) 2003-03-31
US20040024030A1 (en) 2004-02-05
JP2003520233A (ja) 2003-07-02
CA2397686A1 (en) 2001-07-26
MY133572A (en) 2007-11-30
US6608087B1 (en) 2003-08-19
PT1251848E (pt) 2004-10-29
SI1251848T1 (en) 2004-12-31
WO2001052845A1 (en) 2001-07-26
AR027518A1 (es) 2003-04-02
US6930116B2 (en) 2005-08-16
CN1230166C (zh) 2005-12-07

Similar Documents

Publication Publication Date Title
DE60103974D1 (de) Gyrase-inhibitoren und ihre verwendung
NO20032668D0 (no) Gyraseinhibitorer og anvendelser derav
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DE60106423D1 (de) Entzündungshemmende verbindungen und ihre verwendung
NO20042147L (no) Heterocykliske forbindelser og fremgangsmater for anvendelse derav
NO20022656L (no) Caspaseinhibitorer og anvendelse derav
NO20040469L (no) Heterocykliske forbindelser samt fremstilling og anvendelse derav
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
NO20020343D0 (no) Kaspase-inhibitorer og anvendelse derav
ATE424202T1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6- aminopyridine und ihre verwendung
EE200200550A (et) Karbamaatsed kaspaasi inhibiitorid ja nende kasutamine
DE60209486D1 (de) Pyranoindazole und ihre verwendung in der glaukombehandlung
ATE329906T1 (de) Substituierte 2-anilino-benzimidazole und ihre verwendung als nhe-inhibitoren
DE60235252D1 (de) Aromatische methyltransferasen und ihre verwendung
DE60112635D1 (de) Ölzusammensetzung und ihre Verwendung
DE50313157D1 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
DE50206094D1 (de) Substituierte isoindole und ihre verwendung
ATE382040T1 (de) Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren
DE50106596D1 (de) Haftklebemasse und ihre verwendung
EE200300491A (et) 6-asendis asendatud indolinoonid ja nende kasutamine kinaas-inhibiitoritena
DE50008549D1 (de) Triazolotriazinone und ihre verwendung
DE60141871D1 (de) Oligonukleotidmarkierungsstoffe und ihre Verwendung
DE50202730D1 (de) Substituierte isoindole und ihre verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition